Cambrex Co. (CBM) Holdings Cut by Summit Creek Advisors LLC

Summit Creek Advisors LLC decreased its holdings in shares of Cambrex Co. (NYSE:CBM) by 0.2% in the 1st quarter, Holdings Channel reports. The fund owned 227,011 shares of the biotechnology company’s stock after selling 390 shares during the quarter. Summit Creek Advisors LLC’s holdings in Cambrex were worth $8,819,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. Campbell Newman Asset Management Inc. increased its stake in Cambrex by 2.4% during the first quarter. Campbell Newman Asset Management Inc. now owns 14,486 shares of the biotechnology company’s stock worth $563,000 after acquiring an additional 345 shares during the last quarter. Deutsche Bank AG grew its stake in shares of Cambrex by 90.5% in the fourth quarter. Deutsche Bank AG now owns 154,462 shares of the biotechnology company’s stock valued at $5,830,000 after buying an additional 73,393 shares in the last quarter. American Century Companies Inc. acquired a new stake in shares of Cambrex in the fourth quarter valued at $261,000. Geode Capital Management LLC grew its stake in shares of Cambrex by 8.2% in the fourth quarter. Geode Capital Management LLC now owns 353,011 shares of the biotechnology company’s stock valued at $13,329,000 after buying an additional 26,856 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of Cambrex in the fourth quarter valued at $12,632,000.

In other Cambrex news, CFO Gregory Sargen sold 5,802 shares of Cambrex stock in a transaction dated Friday, February 15th. The stock was sold at an average price of $37.45, for a total transaction of $217,284.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Shawn Cavanagh sold 6,769 shares of Cambrex stock in a transaction dated Friday, February 15th. The stock was sold at an average price of $37.60, for a total value of $254,514.40. The disclosure for this sale can be found here. Company insiders own 1.41% of the company’s stock.

Shares of NYSE CBM traded up $0.60 during trading on Monday, reaching $38.71. The stock had a trading volume of 4,321 shares, compared to its average volume of 273,524. The stock has a market capitalization of $1.27 billion, a PE ratio of 14.01, a PEG ratio of 3.31 and a beta of 2.40. Cambrex Co. has a fifty-two week low of $33.80 and a fifty-two week high of $69.43. The company has a current ratio of 3.93, a quick ratio of 2.86 and a debt-to-equity ratio of 0.46.

Cambrex (NYSE:CBM) last released its earnings results on Wednesday, February 13th. The biotechnology company reported $1.44 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.32 by $0.12. The firm had revenue of $212.30 million during the quarter, compared to analyst estimates of $182.49 million. Cambrex had a return on equity of 14.74% and a net margin of 17.37%. Cambrex’s revenue was up 16.5% compared to the same quarter last year. During the same period last year, the business posted $1.26 earnings per share. On average, equities analysts predict that Cambrex Co. will post 1.14 earnings per share for the current year.

A number of brokerages have recently weighed in on CBM. Zacks Investment Research raised Cambrex from a “hold” rating to a “strong-buy” rating and set a $51.00 price objective for the company in a research note on Wednesday, January 9th. ValuEngine cut Cambrex from a “sell” rating to a “strong sell” rating in a research note on Thursday, January 31st. Jefferies Financial Group cut Cambrex from a “buy” rating to a “hold” rating and set a $43.00 price objective for the company. in a research note on Friday, February 22nd. Finally, Craig Hallum dropped their price objective on Cambrex from $71.00 to $45.00 and set a “buy” rating for the company in a research note on Thursday, February 14th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $48.75.

COPYRIGHT VIOLATION NOTICE: This report was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://www.dispatchtribunal.com/2019/04/15/cambrex-co-cbm-holdings-cut-by-summit-creek-advisors-llc.html.

Cambrex Profile

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms.

Featured Story: Blue-Chip Stocks

Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Co. (NYSE:CBM).

Institutional Ownership by Quarter for Cambrex (NYSE:CBM)

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.